SK282570B6 - Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania - Google Patents

Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania Download PDF

Info

Publication number
SK282570B6
SK282570B6 SK1219-96A SK121996A SK282570B6 SK 282570 B6 SK282570 B6 SK 282570B6 SK 121996 A SK121996 A SK 121996A SK 282570 B6 SK282570 B6 SK 282570B6
Authority
SK
Slovakia
Prior art keywords
hydroxy
treatment
bleeding
estradien
progesterone antagonists
Prior art date
Application number
SK1219-96A
Other languages
English (en)
Slovak (sk)
Other versions
SK121996A3 (en
Inventor
Kristof Chwalisz
Klaus St�Ckemann
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of SK121996A3 publication Critical patent/SK121996A3/sk
Publication of SK282570B6 publication Critical patent/SK282570B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1219-96A 1995-02-02 1995-02-02 Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania SK282570B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1995/000394 WO1996023503A1 (de) 1995-02-02 1995-02-02 Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen

Publications (2)

Publication Number Publication Date
SK121996A3 SK121996A3 (en) 1997-05-07
SK282570B6 true SK282570B6 (sk) 2002-10-08

Family

ID=8165951

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1219-96A SK282570B6 (sk) 1995-02-02 1995-02-02 Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania

Country Status (20)

Country Link
US (1) US6451780B1 (ja)
EP (1) EP0806952B1 (ja)
JP (1) JPH10512889A (ja)
KR (1) KR100370908B1 (ja)
AT (1) ATE235907T1 (ja)
AU (1) AU714959B2 (ja)
CA (1) CA2186953C (ja)
DE (1) DE59510626D1 (ja)
DK (1) DK0806952T3 (ja)
ES (1) ES2196063T3 (ja)
FI (1) FI117850B (ja)
HU (1) HU226276B1 (ja)
MX (1) MX9603889A (ja)
NO (1) NO964155L (ja)
NZ (1) NZ287024A (ja)
PL (1) PL316533A1 (ja)
PT (1) PT806952E (ja)
SK (1) SK282570B6 (ja)
UA (1) UA37259C2 (ja)
WO (1) WO1996023503A1 (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO122179B1 (ro) 1999-08-31 2009-02-27 Schering Aktiengesellschaft Utilizarea de mezoprogestine pentru tratamentul şi prevenirea afecţiunilor ginecologice benigne, hormon-dependente
US8193252B1 (en) * 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
US6685626B2 (en) 2001-02-02 2004-02-03 Regeneration Technologies, Inc. Compositions, devices, methods, and kits for induction of adhesions
US20020176893A1 (en) * 2001-02-02 2002-11-28 Wironen John F. Compositions, implants, methods, and kits for closure of lumen openings, repair of ruptured tissue, and for bulking of tissue
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
EP1761231A1 (en) * 2004-06-07 2007-03-14 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
CA2684450C (en) * 2007-04-20 2017-05-30 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding
US20090118253A1 (en) * 2007-11-05 2009-05-07 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
SG10201704858PA (en) 2012-05-31 2017-07-28 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
MX2015004821A (es) 2012-11-02 2015-08-14 Repros Therapeutics Inc Metodos y composiciones para tratar condiciones dependientes de la progesterona.
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
AU2016377702B2 (en) 2015-12-23 2021-03-11 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11208432B2 (en) 2015-12-23 2021-12-28 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN111690031B (zh) 2016-10-07 2021-06-01 欧瑞克制药公司 糖皮质激素受体抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622943A (en) 1992-05-06 1997-04-22 The Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding
WO1993021926A1 (en) * 1992-05-06 1993-11-11 Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding

Also Published As

Publication number Publication date
AU2561195A (en) 1996-08-21
NO964155D0 (no) 1996-10-01
CA2186953A1 (en) 1996-08-08
FI963049A0 (fi) 1996-08-01
PL316533A1 (en) 1997-01-20
UA37259C2 (uk) 2001-05-15
HUT75930A (en) 1997-05-28
SK121996A3 (en) 1997-05-07
PT806952E (pt) 2003-08-29
FI117850B (fi) 2007-03-30
ES2196063T3 (es) 2003-12-16
HU226276B1 (en) 2008-07-28
EP0806952B1 (de) 2003-04-02
HU9602668D0 (en) 1996-11-28
EP0806952A1 (de) 1997-11-19
DK0806952T3 (da) 2003-06-16
KR970704451A (ko) 1997-09-06
WO1996023503A1 (de) 1996-08-08
AU714959B2 (en) 2000-01-13
JPH10512889A (ja) 1998-12-08
KR100370908B1 (ko) 2003-04-10
ATE235907T1 (de) 2003-04-15
MX9603889A (es) 1997-04-30
NZ287024A (en) 2001-03-30
DE59510626D1 (de) 2003-05-08
CA2186953C (en) 2009-11-10
NO964155L (no) 1996-10-01
US6451780B1 (en) 2002-09-17
FI963049A (fi) 1996-10-01

Similar Documents

Publication Publication Date Title
SK282570B6 (sk) Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania
USRE43916E1 (en) Composition for contraception
US5898032A (en) Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US5633242A (en) Pharmaceuticals for contraception/hormone substitution containing a biogenous estrogen component
KR100365879B1 (ko) 프로게스테론길항제및게스타겐을포함하는자궁내막증식증또는자궁평활근종치료제
RU2165258C2 (ru) Фармацевтический комбинированный препарат для гормональной контрацепции
JPH09510183A (ja) 複合避妊薬
SK178097A3 (en) Pharmaceutical combined preparation, kit and method for hormonal contraception
CA2241192A1 (en) Contraceptive process and kit for female mammals that consists of a combination of gestagen and estrogen
AU707235B2 (en) Competitive progesterone antagonists for demand-oriented female birth control
US20030018018A1 (en) Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
WO1999025360A2 (en) Progestogen-antiprogestogen regimens
RU2170580C2 (ru) Антагонисты прогестерона для получения лекарств при лечении дисфункциональных маточных кровотечений
CZ284596A3 (en) Progesterone antagonists for preparing medicaments applied for treating dysfunctional uterine bleeding
Kovacs Luteal contraception
DE4403769A1 (de) Progesteronantagonisten für die Herstellung von Arzneimitteln zur Behandlung von dysfunktionellen uterinen Blutungen
ZA200201614B (en) Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives.
CA2596416A1 (en) Methods of extended use oral contraception